Foreign media spotlight the revaluation of Chinese medical AI! Forbes provides an in-depth analysis of DeShi Technology (02526.HK): iMed-6.0 sweeps both first and second place on two international leaderboards, benchmarking against U.S.-listed Tempus AI.

On November 13, news emerged that the internationally authoritative financial media outlet Forbes recently published an in-depth feature titled "How Chinese Medical AI Is Winning Back the Market," identifying Hong Kong-listed company DIAGENS (02526.HK) as the core touchstone for the revaluation of Chinese medical AI and drawing a deep comparison between it and Tempus AI, the leading medical AI company that has surged 90% on U.S. markets this year. The report noted that on November 12, DIAGENS officially launched to the world its sixth-generation general medical imaging large model iMedImage 6.0 (including the medium-spec version Thoth and the small-spec version Aegis), featuring a completely rebuilt underlying architecture. On the two most authoritative international evaluation benchmarks, MMMU (Health and Medicine) and MedBench VLM, iMed-6.0 swept both first and second place globally, comprehensively outperforming GPT-4V, GPT-5.5, Gemini-3.5-Flash, Claude Opus 4.7, and mainstream domestic general large models; its Aegis model further achieved a clinical breakthrough of "a single chest-abdomen CT scan covering 8 major anatomical regions and accurately detecting 509 diseases and imaging signs." The series launch caused a sensation on the overseas X platform, with a single post surpassing 853,000 views in less than 24 hours. Forbes emphasized that DIAGENS is building the "Microsoft Office of the medical AI world" through its zero-code platform iMedLoop. In the first half of this year, the company's MaaS (Model-as-a-Service) revenue doubled year-on-year to RMB94.5 million, accounting for as much as 87% of total revenue, and within six months it has partnered with 99 hospitals to jointly build 158 specialty diagnostic models. With China's NMPA Class III certification secured, EU CE approval obtained, and U.S. FDA Class II review underway (expected approval in Q1 2027), DIAGENScombining an extremely small free float with high platform-driven growthis becoming the focus of global capital's revaluation of Chinese hard-tech healthcare. (Huatai previously initiated coverage with a "Buy" rating and a target price of HK$296.13.)